A Randomised Controlled Trial of Efficacy of Cognitive Rehabilitation in Multiple Sclerosis: A Cognitive, Behavioural, and MRI Study
- PMID: 28116167
- PMCID: PMC5223046
- DOI: 10.1155/2016/4292585
A Randomised Controlled Trial of Efficacy of Cognitive Rehabilitation in Multiple Sclerosis: A Cognitive, Behavioural, and MRI Study
Abstract
Aim. To explore the efficacy of home-based, computerised, cognitive rehabilitation in patients with multiple sclerosis using neuropsychological assessment and advanced structural and functional magnetic resonance imaging (fMRI). Methods. 38 patients with MS and cognitive impairment on the Brief International Cognitive Assessment for MS (BICAMS) were enrolled. Patients were randomised to undergo 45 minutes of computerised cognitive rehabilitation using RehaCom software (n = 19) three times weekly for six weeks or to a control condition (n = 19). Neuropsychological and MRI data were obtained at baseline (time 1), following the 6-week intervention (time 2), and after a further twelve weeks (time 3). Cortical activations were explored using fMRI and microstructural changes were explored using quantitative magnetisation transfer (QMT) imaging. Results. The treatment group showed a greater improvement in SDMT gain scores between baseline and time 2 compared to the control group (p = 0.005). The treatment group exhibited increased activation in the bilateral prefrontal cortex and right temporoparietal regions relative to control group at time 3 (p < 0.05FWE corrected). No significant changes were observed on QMT. Conclusion. This study supports the hypothesis that home-based, computerised, cognitive rehabilitation may be effective in improving cognitive performance in patients with MS. Clinical trials registration is ISRCTN54901925.
Conflict of interest statement
Dr. J. Campbell and Professor M. Cercignani have nothing to disclose. Dr W. Rashid has accepted educational grants and travel bursaries from Genzyme, Biogen-Idec, Novartis, and Teva and has also participated in advisory boards with Bayer, Novartis, Biogen-Idec, and Genzyme. Professor D. Langdon (i) has received research grants from Bayer, Novartis, and Biogen and has also participated in advisory board with Bayer, Novartis, and Teva is also in the speaker Bureau for Teva, Roche, Bayer, Novartis, and Biogen.
Figures


References
-
- Amato M. P., Ponziani G., Pracucci G., Bracco L., Siracusa G., Amaducci L. Cognitive impairment in early-onset multiple sclerosis: pattern, predictors, and impact on everyday life in a 4-year follow-up. Archives of Neurology. 1995;52(2):168–172. doi: 10.1001/archneur.1995.00540260072019. - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical